Cargando…

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Eun‐Young, Weir, Ashley, Meagher, Nicola S., Farrington, Kyo, Nelson, Gregg S., Ghatage, Prafull, Lee, Cheng‐Han, Riggan, Marjorie J., Bolithon, Adelyn, Popovic, Gordana, Leung, Betty, Tang, Katrina, Lambie, Neil, Millstein, Joshua, Alsop, Jennifer, Anglesio, Michael S., Ataseven, Beyhan, Barlow, Ellen, Beckmann, Matthias W., Berger, Jessica, Bisinotto, Christiani, Bösmüller, Hans, Boros, Jessica, Brand, Alison H., Brooks‐Wilson, Angela, Brucker, Sara Y., Carney, Michael E., Casablanca, Yovanni, Cazorla‐Jiménez, Alicia, Cohen, Paul A., Conrads, Thomas P., Cook, Linda S., Coulson, Penny, Courtney‐Brooks, Madeleine, Cramer, Daniel W., Crowe, Philip, Cunningham, Julie M., Cybulski, Cezary, Darcy, Kathleen M., El‐Bahrawy, Mona A., Elishaev, Esther, Erber, Ramona, Farrell, Rhonda, Fereday, Sian, Fischer, Anna, García, María J., Gayther, Simon A., Gentry‐Maharaj, Aleksandra, Gilks, C. Blake, Grube, Marcel, Harnett, Paul R., Harrington, Shariska Petersen, Harter, Philipp, Hartmann, Arndt, Hecht, Jonathan L., Heikaus, Sebastian, Hein, Alexander, Heitz, Florian, Hendley, Joy, Hernandez, Brenda Y., Polo, Susanna Hernando, Heublein, Sabine, Hirasawa, Akira, Høgdall, Estrid, Høgdall, Claus K., Horlings, Hugo M., Huntsman, David G., Huzarski, Tomasz, Jewell, Andrea, Jimenez‐Linan, Mercedes, Jones, Michael E., Kaufmann, Scott H., Kennedy, Catherine J., Khabele, Dineo, Kommoss, Felix K. F., Kruitwagen, Roy F. P. M., Lambrechts, Diether, Le, Nhu D., Lener, Marcin, Lester, Jenny, Leung, Yee, Linder, Anna, Loverix, Liselore, Lubiński, Jan, Madan, Rashna, Maxwell, G. Larry, Modugno, Francesmary, Neuhausen, Susan L., Olawaiye, Alexander, Olbrecht, Siel, Orsulic, Sandra, Palacios, José, Pearce, Celeste Leigh, Pike, Malcolm C., Quinn, Carmel M., Mohan, Ganendra Raj, Rodríguez‐Antona, Cristina, Ruebner, Matthias, Ryan, Andy, Salfinger, Stuart G., Sasamoto, Naoko, Schildkraut, Joellen M., Schoemaker, Minouk J., Shah, Mitul, Sharma, Raghwa, Shvetsov, Yurii B., Singh, Naveena, Sonke, Gabe S., Steele, Linda, Stewart, Colin J. R., Sundfeldt, Karin, Swerdlow, Anthony J., Talhouk, Aline, Tan, Adeline, Taylor, Sarah E., Terry, Kathryn L., Tołoczko, Aleksandra, Traficante, Nadia, Van de Vijver, Koen K., van der Aa, Maaike A., Van Gorp, Toon, Van Nieuwenhuysen, Els, van‐Wagensveld, Lilian, Vergote, Ignace, Vierkant, Robert A., Wang, Chen, Wilkens, Lynne R., Winham, Stacey J., Wu, Anna H., Benitez, Javier, Berchuck, Andrew, Candido dos Reis, Francisco J., DeFazio, Anna, Fasching, Peter A., Goode, Ellen L., Goodman, Marc T., Gronwald, Jacek, Karlan, Beth Y., Kommoss, Stefan, Menon, Usha, Sinn, Hans‐Peter, Staebler, Annette, Brenton, James D., Bowtell, David D., Pharoah, Paul D. P., Ramus, Susan J., Köbel, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107112/
https://www.ncbi.nlm.nih.gov/pubmed/36572991
http://dx.doi.org/10.1002/cncr.34582
_version_ 1785026534640189440
author Kang, Eun‐Young
Weir, Ashley
Meagher, Nicola S.
Farrington, Kyo
Nelson, Gregg S.
Ghatage, Prafull
Lee, Cheng‐Han
Riggan, Marjorie J.
Bolithon, Adelyn
Popovic, Gordana
Leung, Betty
Tang, Katrina
Lambie, Neil
Millstein, Joshua
Alsop, Jennifer
Anglesio, Michael S.
Ataseven, Beyhan
Barlow, Ellen
Beckmann, Matthias W.
Berger, Jessica
Bisinotto, Christiani
Bösmüller, Hans
Boros, Jessica
Brand, Alison H.
Brooks‐Wilson, Angela
Brucker, Sara Y.
Carney, Michael E.
Casablanca, Yovanni
Cazorla‐Jiménez, Alicia
Cohen, Paul A.
Conrads, Thomas P.
Cook, Linda S.
Coulson, Penny
Courtney‐Brooks, Madeleine
Cramer, Daniel W.
Crowe, Philip
Cunningham, Julie M.
Cybulski, Cezary
Darcy, Kathleen M.
El‐Bahrawy, Mona A.
Elishaev, Esther
Erber, Ramona
Farrell, Rhonda
Fereday, Sian
Fischer, Anna
García, María J.
Gayther, Simon A.
Gentry‐Maharaj, Aleksandra
Gilks, C. Blake
Grube, Marcel
Harnett, Paul R.
Harrington, Shariska Petersen
Harter, Philipp
Hartmann, Arndt
Hecht, Jonathan L.
Heikaus, Sebastian
Hein, Alexander
Heitz, Florian
Hendley, Joy
Hernandez, Brenda Y.
Polo, Susanna Hernando
Heublein, Sabine
Hirasawa, Akira
Høgdall, Estrid
Høgdall, Claus K.
Horlings, Hugo M.
Huntsman, David G.
Huzarski, Tomasz
Jewell, Andrea
Jimenez‐Linan, Mercedes
Jones, Michael E.
Kaufmann, Scott H.
Kennedy, Catherine J.
Khabele, Dineo
Kommoss, Felix K. F.
Kruitwagen, Roy F. P. M.
Lambrechts, Diether
Le, Nhu D.
Lener, Marcin
Lester, Jenny
Leung, Yee
Linder, Anna
Loverix, Liselore
Lubiński, Jan
Madan, Rashna
Maxwell, G. Larry
Modugno, Francesmary
Neuhausen, Susan L.
Olawaiye, Alexander
Olbrecht, Siel
Orsulic, Sandra
Palacios, José
Pearce, Celeste Leigh
Pike, Malcolm C.
Quinn, Carmel M.
Mohan, Ganendra Raj
Rodríguez‐Antona, Cristina
Ruebner, Matthias
Ryan, Andy
Salfinger, Stuart G.
Sasamoto, Naoko
Schildkraut, Joellen M.
Schoemaker, Minouk J.
Shah, Mitul
Sharma, Raghwa
Shvetsov, Yurii B.
Singh, Naveena
Sonke, Gabe S.
Steele, Linda
Stewart, Colin J. R.
Sundfeldt, Karin
Swerdlow, Anthony J.
Talhouk, Aline
Tan, Adeline
Taylor, Sarah E.
Terry, Kathryn L.
Tołoczko, Aleksandra
Traficante, Nadia
Van de Vijver, Koen K.
van der Aa, Maaike A.
Van Gorp, Toon
Van Nieuwenhuysen, Els
van‐Wagensveld, Lilian
Vergote, Ignace
Vierkant, Robert A.
Wang, Chen
Wilkens, Lynne R.
Winham, Stacey J.
Wu, Anna H.
Benitez, Javier
Berchuck, Andrew
Candido dos Reis, Francisco J.
DeFazio, Anna
Fasching, Peter A.
Goode, Ellen L.
Goodman, Marc T.
Gronwald, Jacek
Karlan, Beth Y.
Kommoss, Stefan
Menon, Usha
Sinn, Hans‐Peter
Staebler, Annette
Brenton, James D.
Bowtell, David D.
Pharoah, Paul D. P.
Ramus, Susan J.
Köbel, Martin
author_facet Kang, Eun‐Young
Weir, Ashley
Meagher, Nicola S.
Farrington, Kyo
Nelson, Gregg S.
Ghatage, Prafull
Lee, Cheng‐Han
Riggan, Marjorie J.
Bolithon, Adelyn
Popovic, Gordana
Leung, Betty
Tang, Katrina
Lambie, Neil
Millstein, Joshua
Alsop, Jennifer
Anglesio, Michael S.
Ataseven, Beyhan
Barlow, Ellen
Beckmann, Matthias W.
Berger, Jessica
Bisinotto, Christiani
Bösmüller, Hans
Boros, Jessica
Brand, Alison H.
Brooks‐Wilson, Angela
Brucker, Sara Y.
Carney, Michael E.
Casablanca, Yovanni
Cazorla‐Jiménez, Alicia
Cohen, Paul A.
Conrads, Thomas P.
Cook, Linda S.
Coulson, Penny
Courtney‐Brooks, Madeleine
Cramer, Daniel W.
Crowe, Philip
Cunningham, Julie M.
Cybulski, Cezary
Darcy, Kathleen M.
El‐Bahrawy, Mona A.
Elishaev, Esther
Erber, Ramona
Farrell, Rhonda
Fereday, Sian
Fischer, Anna
García, María J.
Gayther, Simon A.
Gentry‐Maharaj, Aleksandra
Gilks, C. Blake
Grube, Marcel
Harnett, Paul R.
Harrington, Shariska Petersen
Harter, Philipp
Hartmann, Arndt
Hecht, Jonathan L.
Heikaus, Sebastian
Hein, Alexander
Heitz, Florian
Hendley, Joy
Hernandez, Brenda Y.
Polo, Susanna Hernando
Heublein, Sabine
Hirasawa, Akira
Høgdall, Estrid
Høgdall, Claus K.
Horlings, Hugo M.
Huntsman, David G.
Huzarski, Tomasz
Jewell, Andrea
Jimenez‐Linan, Mercedes
Jones, Michael E.
Kaufmann, Scott H.
Kennedy, Catherine J.
Khabele, Dineo
Kommoss, Felix K. F.
Kruitwagen, Roy F. P. M.
Lambrechts, Diether
Le, Nhu D.
Lener, Marcin
Lester, Jenny
Leung, Yee
Linder, Anna
Loverix, Liselore
Lubiński, Jan
Madan, Rashna
Maxwell, G. Larry
Modugno, Francesmary
Neuhausen, Susan L.
Olawaiye, Alexander
Olbrecht, Siel
Orsulic, Sandra
Palacios, José
Pearce, Celeste Leigh
Pike, Malcolm C.
Quinn, Carmel M.
Mohan, Ganendra Raj
Rodríguez‐Antona, Cristina
Ruebner, Matthias
Ryan, Andy
Salfinger, Stuart G.
Sasamoto, Naoko
Schildkraut, Joellen M.
Schoemaker, Minouk J.
Shah, Mitul
Sharma, Raghwa
Shvetsov, Yurii B.
Singh, Naveena
Sonke, Gabe S.
Steele, Linda
Stewart, Colin J. R.
Sundfeldt, Karin
Swerdlow, Anthony J.
Talhouk, Aline
Tan, Adeline
Taylor, Sarah E.
Terry, Kathryn L.
Tołoczko, Aleksandra
Traficante, Nadia
Van de Vijver, Koen K.
van der Aa, Maaike A.
Van Gorp, Toon
Van Nieuwenhuysen, Els
van‐Wagensveld, Lilian
Vergote, Ignace
Vierkant, Robert A.
Wang, Chen
Wilkens, Lynne R.
Winham, Stacey J.
Wu, Anna H.
Benitez, Javier
Berchuck, Andrew
Candido dos Reis, Francisco J.
DeFazio, Anna
Fasching, Peter A.
Goode, Ellen L.
Goodman, Marc T.
Gronwald, Jacek
Karlan, Beth Y.
Kommoss, Stefan
Menon, Usha
Sinn, Hans‐Peter
Staebler, Annette
Brenton, James D.
Bowtell, David D.
Pharoah, Paul D. P.
Ramus, Susan J.
Köbel, Martin
author_sort Kang, Eun‐Young
collection PubMed
description BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High‐level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high‐level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08‐1.47, p = .034, and HR, 1.18; 95% CI, 1.05‐1.32, p = .015, respectively). This was also true for cases with combined high‐level amplification/overexpression (HR, 1.26; 95% CI, 1.09‐1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1‐SD increase; 95% CI, 0.94‐1.06; p = .58). CCNE1 high‐level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large‐scale validation that CCNE1 high‐level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.
format Online
Article
Text
id pubmed-10107112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101071122023-04-18 CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study Kang, Eun‐Young Weir, Ashley Meagher, Nicola S. Farrington, Kyo Nelson, Gregg S. Ghatage, Prafull Lee, Cheng‐Han Riggan, Marjorie J. Bolithon, Adelyn Popovic, Gordana Leung, Betty Tang, Katrina Lambie, Neil Millstein, Joshua Alsop, Jennifer Anglesio, Michael S. Ataseven, Beyhan Barlow, Ellen Beckmann, Matthias W. Berger, Jessica Bisinotto, Christiani Bösmüller, Hans Boros, Jessica Brand, Alison H. Brooks‐Wilson, Angela Brucker, Sara Y. Carney, Michael E. Casablanca, Yovanni Cazorla‐Jiménez, Alicia Cohen, Paul A. Conrads, Thomas P. Cook, Linda S. Coulson, Penny Courtney‐Brooks, Madeleine Cramer, Daniel W. Crowe, Philip Cunningham, Julie M. Cybulski, Cezary Darcy, Kathleen M. El‐Bahrawy, Mona A. Elishaev, Esther Erber, Ramona Farrell, Rhonda Fereday, Sian Fischer, Anna García, María J. Gayther, Simon A. Gentry‐Maharaj, Aleksandra Gilks, C. Blake Grube, Marcel Harnett, Paul R. Harrington, Shariska Petersen Harter, Philipp Hartmann, Arndt Hecht, Jonathan L. Heikaus, Sebastian Hein, Alexander Heitz, Florian Hendley, Joy Hernandez, Brenda Y. Polo, Susanna Hernando Heublein, Sabine Hirasawa, Akira Høgdall, Estrid Høgdall, Claus K. Horlings, Hugo M. Huntsman, David G. Huzarski, Tomasz Jewell, Andrea Jimenez‐Linan, Mercedes Jones, Michael E. Kaufmann, Scott H. Kennedy, Catherine J. Khabele, Dineo Kommoss, Felix K. F. Kruitwagen, Roy F. P. M. Lambrechts, Diether Le, Nhu D. Lener, Marcin Lester, Jenny Leung, Yee Linder, Anna Loverix, Liselore Lubiński, Jan Madan, Rashna Maxwell, G. Larry Modugno, Francesmary Neuhausen, Susan L. Olawaiye, Alexander Olbrecht, Siel Orsulic, Sandra Palacios, José Pearce, Celeste Leigh Pike, Malcolm C. Quinn, Carmel M. Mohan, Ganendra Raj Rodríguez‐Antona, Cristina Ruebner, Matthias Ryan, Andy Salfinger, Stuart G. Sasamoto, Naoko Schildkraut, Joellen M. Schoemaker, Minouk J. Shah, Mitul Sharma, Raghwa Shvetsov, Yurii B. Singh, Naveena Sonke, Gabe S. Steele, Linda Stewart, Colin J. R. Sundfeldt, Karin Swerdlow, Anthony J. Talhouk, Aline Tan, Adeline Taylor, Sarah E. Terry, Kathryn L. Tołoczko, Aleksandra Traficante, Nadia Van de Vijver, Koen K. van der Aa, Maaike A. Van Gorp, Toon Van Nieuwenhuysen, Els van‐Wagensveld, Lilian Vergote, Ignace Vierkant, Robert A. Wang, Chen Wilkens, Lynne R. Winham, Stacey J. Wu, Anna H. Benitez, Javier Berchuck, Andrew Candido dos Reis, Francisco J. DeFazio, Anna Fasching, Peter A. Goode, Ellen L. Goodman, Marc T. Gronwald, Jacek Karlan, Beth Y. Kommoss, Stefan Menon, Usha Sinn, Hans‐Peter Staebler, Annette Brenton, James D. Bowtell, David D. Pharoah, Paul D. P. Ramus, Susan J. Köbel, Martin Cancer ORIGINAL ARTICLES BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High‐level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high‐level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08‐1.47, p = .034, and HR, 1.18; 95% CI, 1.05‐1.32, p = .015, respectively). This was also true for cases with combined high‐level amplification/overexpression (HR, 1.26; 95% CI, 1.09‐1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1‐SD increase; 95% CI, 0.94‐1.06; p = .58). CCNE1 high‐level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large‐scale validation that CCNE1 high‐level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC. John Wiley and Sons Inc. 2022-12-26 2023-03-01 /pmc/articles/PMC10107112/ /pubmed/36572991 http://dx.doi.org/10.1002/cncr.34582 Text en © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ORIGINAL ARTICLES
Kang, Eun‐Young
Weir, Ashley
Meagher, Nicola S.
Farrington, Kyo
Nelson, Gregg S.
Ghatage, Prafull
Lee, Cheng‐Han
Riggan, Marjorie J.
Bolithon, Adelyn
Popovic, Gordana
Leung, Betty
Tang, Katrina
Lambie, Neil
Millstein, Joshua
Alsop, Jennifer
Anglesio, Michael S.
Ataseven, Beyhan
Barlow, Ellen
Beckmann, Matthias W.
Berger, Jessica
Bisinotto, Christiani
Bösmüller, Hans
Boros, Jessica
Brand, Alison H.
Brooks‐Wilson, Angela
Brucker, Sara Y.
Carney, Michael E.
Casablanca, Yovanni
Cazorla‐Jiménez, Alicia
Cohen, Paul A.
Conrads, Thomas P.
Cook, Linda S.
Coulson, Penny
Courtney‐Brooks, Madeleine
Cramer, Daniel W.
Crowe, Philip
Cunningham, Julie M.
Cybulski, Cezary
Darcy, Kathleen M.
El‐Bahrawy, Mona A.
Elishaev, Esther
Erber, Ramona
Farrell, Rhonda
Fereday, Sian
Fischer, Anna
García, María J.
Gayther, Simon A.
Gentry‐Maharaj, Aleksandra
Gilks, C. Blake
Grube, Marcel
Harnett, Paul R.
Harrington, Shariska Petersen
Harter, Philipp
Hartmann, Arndt
Hecht, Jonathan L.
Heikaus, Sebastian
Hein, Alexander
Heitz, Florian
Hendley, Joy
Hernandez, Brenda Y.
Polo, Susanna Hernando
Heublein, Sabine
Hirasawa, Akira
Høgdall, Estrid
Høgdall, Claus K.
Horlings, Hugo M.
Huntsman, David G.
Huzarski, Tomasz
Jewell, Andrea
Jimenez‐Linan, Mercedes
Jones, Michael E.
Kaufmann, Scott H.
Kennedy, Catherine J.
Khabele, Dineo
Kommoss, Felix K. F.
Kruitwagen, Roy F. P. M.
Lambrechts, Diether
Le, Nhu D.
Lener, Marcin
Lester, Jenny
Leung, Yee
Linder, Anna
Loverix, Liselore
Lubiński, Jan
Madan, Rashna
Maxwell, G. Larry
Modugno, Francesmary
Neuhausen, Susan L.
Olawaiye, Alexander
Olbrecht, Siel
Orsulic, Sandra
Palacios, José
Pearce, Celeste Leigh
Pike, Malcolm C.
Quinn, Carmel M.
Mohan, Ganendra Raj
Rodríguez‐Antona, Cristina
Ruebner, Matthias
Ryan, Andy
Salfinger, Stuart G.
Sasamoto, Naoko
Schildkraut, Joellen M.
Schoemaker, Minouk J.
Shah, Mitul
Sharma, Raghwa
Shvetsov, Yurii B.
Singh, Naveena
Sonke, Gabe S.
Steele, Linda
Stewart, Colin J. R.
Sundfeldt, Karin
Swerdlow, Anthony J.
Talhouk, Aline
Tan, Adeline
Taylor, Sarah E.
Terry, Kathryn L.
Tołoczko, Aleksandra
Traficante, Nadia
Van de Vijver, Koen K.
van der Aa, Maaike A.
Van Gorp, Toon
Van Nieuwenhuysen, Els
van‐Wagensveld, Lilian
Vergote, Ignace
Vierkant, Robert A.
Wang, Chen
Wilkens, Lynne R.
Winham, Stacey J.
Wu, Anna H.
Benitez, Javier
Berchuck, Andrew
Candido dos Reis, Francisco J.
DeFazio, Anna
Fasching, Peter A.
Goode, Ellen L.
Goodman, Marc T.
Gronwald, Jacek
Karlan, Beth Y.
Kommoss, Stefan
Menon, Usha
Sinn, Hans‐Peter
Staebler, Annette
Brenton, James D.
Bowtell, David D.
Pharoah, Paul D. P.
Ramus, Susan J.
Köbel, Martin
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
title CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
title_full CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
title_fullStr CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
title_full_unstemmed CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
title_short CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
title_sort ccne1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: an ovarian tumor tissue analysis consortium study
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107112/
https://www.ncbi.nlm.nih.gov/pubmed/36572991
http://dx.doi.org/10.1002/cncr.34582
work_keys_str_mv AT kangeunyoung ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT weirashley ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT meaghernicolas ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT farringtonkyo ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT nelsongreggs ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT ghatageprafull ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT leechenghan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT rigganmarjoriej ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT bolithonadelyn ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT popovicgordana ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT leungbetty ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT tangkatrina ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT lambieneil ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT millsteinjoshua ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT alsopjennifer ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT anglesiomichaels ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT atasevenbeyhan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT barlowellen ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT beckmannmatthiasw ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT bergerjessica ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT bisinottochristiani ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT bosmullerhans ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT borosjessica ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT brandalisonh ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT brookswilsonangela ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT bruckersaray ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT carneymichaele ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT casablancayovanni ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT cazorlajimenezalicia ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT cohenpaula ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT conradsthomasp ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT cooklindas ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT coulsonpenny ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT courtneybrooksmadeleine ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT cramerdanielw ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT crowephilip ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT cunninghamjuliem ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT cybulskicezary ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT darcykathleenm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT elbahrawymonaa ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT elishaevesther ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT erberramona ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT farrellrhonda ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT feredaysian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT fischeranna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT garciamariaj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT gaythersimona ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT gentrymaharajaleksandra ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT gilkscblake ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT grubemarcel ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT harnettpaulr ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT harringtonshariskapetersen ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT harterphilipp ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT hartmannarndt ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT hechtjonathanl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT heikaussebastian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT heinalexander ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT heitzflorian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT hendleyjoy ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT hernandezbrenday ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT polosusannahernando ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT heubleinsabine ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT hirasawaakira ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT høgdallestrid ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT høgdallclausk ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT horlingshugom ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT huntsmandavidg ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT huzarskitomasz ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT jewellandrea ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT jimenezlinanmercedes ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT jonesmichaele ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT kaufmannscotth ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT kennedycatherinej ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT khabeledineo ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT kommossfelixkf ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT kruitwagenroyfpm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT lambrechtsdiether ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT lenhud ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT lenermarcin ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT lesterjenny ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT leungyee ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT linderanna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT loverixliselore ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT lubinskijan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT madanrashna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT maxwellglarry ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT modugnofrancesmary ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT neuhausensusanl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT olawaiyealexander ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT olbrechtsiel ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT orsulicsandra ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT palaciosjose ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT pearcecelesteleigh ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT pikemalcolmc ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT quinncarmelm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT mohanganendraraj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT rodriguezantonacristina ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT ruebnermatthias ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT ryanandy ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT salfingerstuartg ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT sasamotonaoko ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT schildkrautjoellenm ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT schoemakerminoukj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT shahmitul ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT sharmaraghwa ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT shvetsovyuriib ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT singhnaveena ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT sonkegabes ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT steelelinda ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT stewartcolinjr ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT sundfeldtkarin ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT swerdlowanthonyj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT talhoukaline ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT tanadeline ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT taylorsarahe ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT terrykathrynl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT tołoczkoaleksandra ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT traficantenadia ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT vandevijverkoenk ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT vanderaamaaikea ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT vangorptoon ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT vannieuwenhuysenels ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT vanwagensveldlilian ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT vergoteignace ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT vierkantroberta ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT wangchen ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT wilkenslynner ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT winhamstaceyj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT wuannah ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT benitezjavier ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT berchuckandrew ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT candidodosreisfranciscoj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT defazioanna ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT faschingpetera ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT goodeellenl ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT goodmanmarct ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT gronwaldjacek ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT karlanbethy ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT kommossstefan ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT menonusha ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT sinnhanspeter ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT staeblerannette ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT brentonjamesd ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT bowtelldavidd ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT pharoahpauldp ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT ramussusanj ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy
AT kobelmartin ccne1andsurvivalofpatientswithtuboovarianhighgradeserouscarcinomaanovariantumortissueanalysisconsortiumstudy